what is the leading stock segment in the pharmaceutical field?

China pharmaceutical leading stock refers to a company with a leading position and market share in the pharmaceutical industry in China. These companies include Xi 'an Janssen Pharmaceutical Companies, Haisike Pharmaceutical, Hengrui Pharma, China Biopharmaceutical, Unacon, Jiuzhitang Pharmaceutical and Kelun Pharmaceutical. The following small series brings the breakdown of stock leaders in the medical field. Let's take a look at it together, hoping to bring reference.

What are the leading stocks of stock medicine

Domestic generic drug leading stocks: Hengrui Pharma, Huadong Pharmaceutical, Huahai Pharmaceutical, Puli Pharmaceutical, Jingxin Pharmaceutical and Xinlitai.

tonghua dongbao, a second-generation insulin leader, Hualan Bio, a blood product leader, Kangtai Bio, a Miao leader (this is controversial and needs to be subdivided), Fuhong Hanlin, a monoclonal antibody leader (monoclonal antibodies are scattered and there are many enterprises in the layout, Haizheng Bio, Jiahe, etc.), Changchun Gaoxin, a growth hormone leader, and Wuwu Bio, an antiallergic drug leader.

Baiyun Mountain 6332: Baiyun Mountain's brand awareness and reputation have great influence and attraction among consumers all over the country, and it is one of the most valuable pharmaceutical brands in China; Kunyao Group 6422: The annual profit of the pharmaceutical industry in 215 is expected to be 26.2 billion yuan, up 19% year-on-year, and the growth rate dropped by .4 percentage points year-on-year.

The list of "pharmaceutical leading stocks" with heavy foreign positions includes Mindray Medical, Hengrui Pharma, Shanghai Pharmaceutical, Baiyun Mountain and Changchun High-tech.

What are the leading pharmaceutical stocks in China?

Hello, there are these Hengrui Pharma 6276: the leading innovative pharmaceutical company in China, with increasing R&D ratio. It is also the largest research and production base of anti-tumor and surgical drugs and contrast agents in China.

The list of "pharmaceutical leading stocks" with heavy foreign positions includes Mindray Medical, Hengrui Pharma, Shanghai Pharmaceutical, Baiyun Mountain and Changchun High-tech.

Hengrui Pharma (6276) is the first innovative drug in China. The main product lines are anti-tumor, anesthesia, contrast agent and so on. The company's return on net assets has remained above 23% for many years, and its net profit has maintained a growth rate of above 2% for many years. The company's research and development strength is very strong, the management team is excellent, and the sales ability is also very strong.

medical cosmetology, referred to as medical cosmetology for short, refers to a cosmetic method that uses traumatic or irreversible medical technologies such as drugs, surgery and medical devices to repair and reshape human appearance and various parts of the human body.

The leading stocks of listed pharmaceutical companies are Tencent Holdings Limited, Yaoming Bio, and China Bio-Pharmaceutical. Tencent Holdings Limited (7.HK): Tencent Medical Health, a pharmaceutical subsidiary of Tencent, is one of the leading Internet medical platforms in China and one of the leading enterprises in the pharmaceutical industry.

The leading stocks of listed pharmaceutical companies in p>223 are as follows: ST Yikang (15), up 45%. ST Furen (6781), an increase of 72%. Chengxin Pharmaceutical (63811), with an increase of 77%. Chengdu pioneer (688,222), up 62%. Xingqi Eye Drops (3573), up 69%.

What are the listed companies of pharmaceutical concepts

Hengrui Pharma (6276): The company's business includes drug research and development, production and sales.

Wuxi pharmatech (63259): The company is engaged in pharmaceutical research and development services.

Aier Ophthalmology (315): The company's main business is ophthalmology medical service and optometry medical service.

Zhifei Bio (3122): The company's business includes research and development, production and sales of vaccines and biological products.

Pien Tze Huang (6436): The company's main business is Chinese patent medicine manufacturing and medicine circulation.

Yunnan Baiyao (538): The company's business includes pharmaceutical research, production and sales.

fosun pharma (6196): the company's business includes pharmaceutical manufacturing and research and development.

tiger medicine (3347): the company's main business is professional clinical research services.

Huadong Pharmaceutical (963): The company's business includes pharmaceutical industrial production and pharmaceutical commercial distribution.

junshi bio (68818): the company's business includes biopharmaceuticals.

Changchun High-tech (661): The company's business includes research and development, production and sales of biopharmaceuticals and Chinese patent medicines.

kanglong huacheng (3759): the company is engaged in the research and development of small molecule drugs.

Shanghai Pharmaceutical (6167): The company is mainly engaged in pharmaceutical R&D and manufacturing, distribution and retail.

tong ren Tang (685): the company's main business is the production and sales of Chinese patent medicines.

watson biological (3142): The company's main business is research and development, production and sales of biotechnological medicines such as vaccines for human use.

what are the leading stocks in biomedical stocks?

1. Hengrui Pharma (6276) is the first innovative drug in China. The main product lines are anti-tumor, anesthesia, contrast agent and so on. The company's net < P > return on assets has remained above 23% for many years, and its net profit has maintained a growth rate of above 2% for many years. The company's R&D strength is very strong,

the management team is excellent, and the sales ability is also very strong. Second, Aier Ophthalmology (315), the first unit of domestic ophthalmology chain hospitals. Mainly to provide patients with a variety of ophthalmic disease diagnosis, ___

and medical optometry and other ophthalmic medical services. The company's return on net assets has remained around 2% for many years, and its net profit has maintained a growth rate of over 3%

for many years. The company's business model is excellent, and its business ability and brand reputation continue to increase. 3. Mindray Medical (376), the first domestic medical device. The main product lines include life and information support, in vitro diagnosis, medical < P > imaging and so on. The company's return on net assets has remained above 25% for many years, and its net profit has maintained a growth rate of above 25% for many years. As

the leading medical device in the global layout, the company has made steady progress in high-end and platformization, with a very stable position and huge long-term space. Four, Changchun High-tech (661), the first domestic biopharmaceutical. The main product lines are growth hormone and syncytial virus vaccine. Company

' s return on net assets has remained above 16% for many years, and its net profit has maintained a growth rate of over 3% for many years. As the leader of biomedical < P > drugs in China, the company's performance has exceeded expectations. Five, WuXi PharmaTech (63259), the first domestic medical research and development services. The main business is the discovery, research and development of small molecular chemicals and the all-round and integrated platform service for the production of < P >. The company's return on net assets has remained above 2% for many years, and its net profit has remained at 25% for many years, growing at a speed of < P >. The company is the world's leading pharmaceutical R&D service platform, with broad market space and expected rapid growth in performance. Six, Tiger Medicine (3347), the leading clinical contract research organization (CRO) in China. The main business is to provide

clinical research services such as technical services and data management for phase I to IV clinical trials for pharmaceutical product research and development. The company's return on net assets has increased to about 17%

in recent two years, and its net profit has maintained a growth rate of more than 56% for many years. Seven, my martial arts (3357), the first domestic desensitization diagnosis and treatment. The company's Dermatophagoides farinae drops keep growing at a high speed, and the heavy product Huanghua < P > Artemisia pollen sublingual drops enter the field for verification, which is expected to be approved for listing in 22. The company's return on net assets has remained at 21% < P > for many years, and its net profit has maintained a growth rate of more than 25% for many years. As the only leading enterprise of sublingual desensitization in China at present, the company has excellent competition pattern < P >, with a market share of over 8%, and the company has great long-term growth potential. Eight, Tongce Medical (6763), the first domestic dental chain. The company develops the layout of stomatological chain hospitals through the mode of "hospital can be replicated+doctor can be replicated+team can be replicated"

. The company's return on net assets has remained at around 23% for many years, and its net profit has maintained a growth rate of around 5% for many years. China's dental market has a vast space, and the company is expected to achieve rapid development under the two major trends of aging population and consumption upgrading. Nine, An _ _ _ Bio (63658), the leading stock of domestic IVD. The company is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and their supporting instruments. The company's return on net assets has remained around 3% for many years, and its net profit has maintained a growth rate of more than 25% for many years. Chemiluminescence industry will enter the era of differentiation. With 7% biological raw material assets, mainstream projects, assembly lines and other advantages, the company is expected to continue to replace foreign capital and other domestic products and maintain sustained growth. X. Hualan Bio (27) is the leading stock of domestic blood products. The company's main product lines are blood products and _ _ _ Miao products. The company's return on net assets has remained around 19% for many years, and its net profit has maintained a growth rate of around 3% for many years. With the slow recovery of domestic blood products industry and the continuous increase of influenza vaccine, the company's performance is expected to be further improved.

A list of biomedical stock leaders

On March 21st, three pharmaceutical companies with a market value of over 1 billion announced their annual reports for 222. Among them, Wuxi PharmaTech's revenue hit a record high last year, and its net profit increased by 7%. The revenue of Wan Tai Bio, which specializes in _ _ _ vaccine and in-vitro diagnosis, nearly doubled, and the net profit increased by over 13%; The net profit of Zhifei Bio, another Miao enterprise, fell by 26% year-on-year.

Financial Investment News

According to WIND's statistics, 19 enterprises in Shenwan's pharmaceutical and biological industries have published annual reports, of which 16 have increased their net profit year-on-year. Perhaps it was supported by strong performance that the pharmaceutical sector rose strongly on March 21, and Wuxi PharmaTech's share price rose by 8.5%.

WuXi PharmaTech's business record

The annual report of WuXi PharmaTech in the pharmaceutical R&D service industry shows that in 222, the company achieved an operating income of 39.355 billion yuan, a record increase of 71.84%. The net profit attributable to shareholders of the parent company was 8.814 billion yuan, a year-on-year increase of 72.91%.

in terms of business, Wuxi pharmatech's chemical business, testing business, biological business, cell and gene therapy CTDMO business have grown, among which the revenue from chemical business has increased by more than 15%. Only the revenue of domestic new drug research and development service department decreased by 22.49% year-on-year, and the revenue during the period was 97 million yuan.

Last year, the growth of new customers of Yaoming Kangde was also obvious. Wuxi pharmatech said in its annual report that in 222, the company added more than 1,4 new customers and the number of active customers exceeded 5,95. The company's income from original customers was 37.781 billion yuan, up 77% year-on-year; The income from new customers was 1.573 billion yuan. The income from enterprises was 18.421 billion yuan, a year-on-year increase of 174%; The income from other customers around the world was 2.934 billion yuan, a year-on-year increase of 3%.

meanwhile, Wuxi pharmatech's R&D expenditure increased by over 7% last year, reaching 1.614 billion yuan, accounting for 4.1% of revenue. WuXi PharmaTech said that the increase in R&D expenses was mainly due to the company's continuous increase in R&D investment, and further strengthening its service capabilities for new molecular types such as PROTAC, oligonucleotide drugs, polypeptide drugs, conjugated drugs, double antibodies, cells and genes.

The performance of the two _ _ _ _ _ Miao leaders has gone in the opposite direction

In addition to Wuxi PharmaTech, Zhifei Bio and Wan Tai Bio, two billion-dollar enterprises whose main products are _ _ _ _ _ Miao, also published annual reports.

zhifei bio-annual report shows that in 222, the company achieved operating income of 38.264 billion yuan, a year-on-year increase of 24.83%; The net profit attributable to shareholders of the parent company was 7.539 billion yuan, a year-on-year decrease of 26.15%. The basic earnings per share was 4.711 yuan, a year-on-year decrease of 26.15%.

As for the reasons for the decline in performance, Zhifei Bio believes that in 222, due to objective factors, the market demand and competition pattern of some products of the company changed greatly, and its sales volume dropped significantly compared with last year. However, with the improvement of people's health awareness and willingness to vaccinate, the market potential of non-exempt _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

in p>222, the R&D expenditure of Zhifei Bio was 854 million yuan, up 54.56% year-on-year.

zhifei bio's main business is _ _ _ seedlings, research and development of biological products, etc. Independent products include ACYW135 polysaccharide seedlings, AC combined seedlings, Hib seedlings and AC polysaccharide seedlings. The agent products include tetravalent HPV___ _ _ vaccine, nine-valent HPV___ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Wan Tai Bio achieved revenue of 11.185 billion yuan last year, up 94.51% year-on-year; The net profit attributable to shareholders of listed companies was 4.736 billion yuan, a year-on-year increase of 134.27%; The basic earnings per share is 5.31 yuan.

Wan Tai biological main _ _ _ vaccine and in vitro diagnosis. Among them, the income of _ _ _ vaccine and in vitro diagnosis both increased, and the income of _ _ _ vaccine division increased by over 152%. The diagnosis division realized a net profit of 817,665,5 yuan, accounting for 16.81%; _ _ _ Miao Branch realized a net profit of 4,45,635,7 yuan, accounting for 83.19%.

Wan Tai Bio said that the company's bivalent cervical cancer vaccine continued to maintain a booming production and sales, and its income and profit continued to grow at a high speed. Its designed production capacity is 3 million pieces per year, and its sales volume exceeds 25 million pieces, and it has successively obtained the listing licenses of Morocco, Nepal, Thailand and Democratic Republic of the Congo. The phase III clinical trial of nine-valent HPV vaccine is progressing smoothly.

Brokers are optimistic about the overall recovery of routine medical needs

In addition to the above-mentioned three leading pharmaceutical stocks, 16 other companies in the pharmaceutical biological sector have published annual reports based on the first-class industry classification of Shenwan. Of the 19 companies, 16 achieved positive growth in net profit year-on-year, with Wan Tai Bio-and Wuxi PharmaTech leading the way.

in terms of market performance, supported by strong performance, the pharmaceutical sector rebounded strongly on March 21st, with Shenwan Pharmaceutical Bio-sector rising by 2.4%, Prius and Panlong Pharmaceutical's share prices rising by 14.39% and 1% respectively, while Wuxi PharmaTech's share price rose by 8.46%, with a turnover of 4.4 billion yuan and a share price of 8.26 yuan. The share prices of Changchun Gaoxin, Jiuzhou Pharmaceutical and Kanglong Huacheng all rose by over 7%, while Wan Tai Bio rose by over 3.7%.

Capital Securities said that with the end of the _ _ _ policy suppression factor, the _ _ _ policy bottom-up feature of the pharmaceutical industry is remarkable, and the valuation contraction has ended. At this stage, the pharmaceutical sector already has a high investment cost performance ratio, and it once again welcomes a good opportunity for allocation. From the perspective of business trend, the disturbance of _ _ _ policy to the performance of pharmaceutical and medical device product companies, especially pharmaceutical industry companies, has gradually come to an end, and the follow-up is about to enter a new profit growth cycle.

Shen Wanhongyuan expects that the demand for routine medical care will fully recover in 223. The medical part of the _ _ _ work report fully affirmed the successful reduction of the medical burden by the policy of controlling fees such as centralized procurement in the past few years. At the same time, it is mentioned that in the future, it is necessary to promote the expansion and sinking of high-quality medical resources, strengthen the guarantee of old-age services, and improve the policy of maternity support. It is expected that continuous fee control will remain the main line of the _ _ _ policy, and independent innovation, ethnic medicine, self-controllable industrial chain, AI+ medical care and vitamin price increase are the current investment directions.